Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Bought by Strs Ohio

Strs Ohio raised its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 18.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,200 shares of the biotechnology company’s stock after acquiring an additional 4,000 shares during the period. Strs Ohio owned 0.09% of Arcturus Therapeutics worth $794,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of ARCT. New York State Teachers Retirement System purchased a new stake in shares of Arcturus Therapeutics in the third quarter valued at about $53,000. China Universal Asset Management Co. Ltd. grew its position in shares of Arcturus Therapeutics by 352.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,406 shares during the last quarter. Arizona State Retirement System acquired a new stake in shares of Arcturus Therapeutics in the fourth quarter valued at approximately $211,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in shares of Arcturus Therapeutics by 5.9% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,853 shares of the biotechnology company’s stock valued at $277,000 after purchasing an additional 606 shares during the last quarter. Finally, Stratos Wealth Partners LTD. acquired a new stake in shares of Arcturus Therapeutics in the third quarter valued at approximately $301,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Down 3.4 %

Shares of Arcturus Therapeutics stock opened at $26.98 on Thursday. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $17.52 and a fifty-two week high of $43.81. The firm has a market cap of $726.30 million, a PE ratio of -25.94 and a beta of 2.60. The business’s fifty day moving average is $34.18 and its two-hundred day moving average is $29.81.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.69) by $1.37. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. The company had revenue of $33.99 million for the quarter, compared to analyst estimates of $64.14 million. Equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.83 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th. Citigroup increased their price target on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Thursday, February 8th. Finally, William Blair restated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Friday, March 8th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Arcturus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $61.33.

Insider Buying and Selling

In related news, COO Pad Chivukula sold 8,565 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $35.01, for a total value of $299,860.65. Following the transaction, the chief operating officer now directly owns 490,883 shares of the company’s stock, valued at approximately $17,185,813.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 13.80% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.